Skip to search formSkip to main contentSkip to account menu

azatoxin

Known as: 1H,6H-3-one-5,4,11,11a-tetrahydro-5-(3,5-dimethoxy-4-hydroxyphenyl)oxazolo(3',4'-1,6)pyrido(3,4-b)indole 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

IndolesTopoisomerase II Inhibitors

Narrower (2)

NSC 640737NSC 640737-M

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
New somatostatin-drug conjugates for effective targeting pancreatic cancer.
Review
2005
Review
2005
Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents.
  • Youngjae You
  • Current pharmaceutical design
  • 2005
  • Corpus ID: 24801613
Podophyllotoxin is an antimitotic natural product. Its inhibitory activity on cell growth led to the development of the… 
Highly Cited
2004
Highly Cited
2004
Lignans and neolignans as lead compounds
Many lignans and neolignans have served as lead compounds for the development of new drugs. Perhaps the best known example is… 
2004
2004
A Mutation in Escherichia coli DNA Gyrase Conferring Quinolone Resistance Results in Sensitivity to Drugs Targeting Eukaryotic Topoisomerase II
ABSTRACT Fluoroquinolones are broad-spectrum antimicrobial agents that target type II topoisomerases. Many fluoroquinolones are… 
Highly Cited
2001
Highly Cited
2001
The synthesis of amino-acid functionalized beta-carbolines as topoisomerase II inhibitors.
1999
1999
Molecular Analysis of Yeast and Human Type II Topoisomerases
The DNA sequence selectivity of topoisomerase II (top2)-DNA cleavage complexes was examined for the human (top2α), yeast, and… 
1997
1997
Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
One approach to broadening the diversity of topoisomerase II-targeted anticancer agents is to generate novel compounds by… 
Highly Cited
1994
Highly Cited
1994
Effects of DNA methylation on topoisomerase I and II cleavage activities.
Highly Cited
1994
Highly Cited
1994
Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
BACKGROUND The cumulative cardiotoxicity of anthracyclines is thought to result from the generation of free radicals. New DNA… 
Highly Cited
1992
Highly Cited
1992
Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.
Azatoxin [NSC 640737-M; 5.R,11aS-1H,6H,3-one-5,4,11,11a-tetrahydro-5-(3,5-dimethoxy-4-hydr oxyphenyl) oxazolo (3',4':1,6)pyrido… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)